Pipeline
Oxford BioTherapeutics is Pioneering the Discovery of Novel Oncology Targets for Solid Tumours
We bring 20 years of innovation to the ADC and TCE field. In addition to our own, proprietary pipeline of ADC and TCE candidates we have a number of partnerships and collaborations that leverage our OGAP®-Verify technology.
OBT076
Clinical Collaboration
Indication
Advanced or refractory solid tumours
Modality
ADC/mAb
Target
CD205 and PD-1
OBT076
Clinical Collaboration
Indication
Adenoid cystic carcinomas of the head and neck
Modality
ADC
Target
CD205
